세계의 세마글루티드(Semaglutide) 시장 : 규모, 점유율, 동향 분석(제품별, 용도별, 투여 경로별, 유통 채널별, 지역별), 부문별 예측(2025-2035년)

Semaglutide Market Growth & Trends:

The global semaglutide market size is anticipated to reach USD 93.60 billion by 2035, growing at a CAGR of 10.47% during the forecast period, according to a new report by Grand View Research, Inc. The semaglutide industry is experiencing growth, driven by the increasing prevalence of diabetes and obesity worldwide. The rising demand for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in diabetes management has positioned semaglutide as a key therapeutic option. The market is influenced by regulatory approvals, expansion in clinical indications, and growing healthcare expenditures that support the adoption of advanced diabetes and obesity treatments.

The primary drivers of the market for semaglutide include the increasing burden of type 2 diabetes and obesity, which have escalated the demand for effective therapeutic interventions. The drug's efficacy in reducing cardiovascular risks and aiding weight management has led to expanded usage beyond diabetes treatment. Additionally, favorable reimbursement policies and the growing adoption of self-administered injectable therapies contribute to market growth. Continuous research and development (R&D) activities aimed at improving drug delivery mechanisms further enhance its commercial potential.

The market presents opportunities for expansion in emerging economies due to rising healthcare infrastructure investments and increasing awareness of diabetes management. There is also potential for further market penetration in obesity treatment, as semaglutide has demonstrated efficacy in weight reduction, leading to regulatory approvals in multiple regions. Pharmaceutical companies are actively exploring novel formulations, including oral versions and combination therapies, to enhance patient compliance and broaden market reach.

The semaglutide industry is characterized by high R&D investment, stringent regulatory oversight, and strong intellectual property protection. Leading pharmaceutical firms dominate the landscape, leveraging extensive distribution networks and partnerships to expand their market presence. The competitive environment is shaped by ongoing clinical trials, product lifecycle management strategies, and efforts to differentiate products through formulation advancements and expanded indications.

Semaglutide is protected by multiple patents that cover its formulation, manufacturing process, and therapeutic applications. The primary patent for semaglutide extends into the 2030s, limiting generic competition and ensuring continued market exclusivity for key manufacturers. Companies investing in alternative formulations, such as oral and extended-release versions, seek additional patent protections to extend commercial viability beyond initial expiration dates.

Recent market instances include regulatory approvals for semaglutide in new therapeutic areas, such as obesity treatment, which has significantly expanded its commercial potential. Market leaders have also engaged in strategic collaborations and acquisitions to strengthen distribution capabilities. Additionally, clinical trial results demonstrating superior efficacy compared to existing therapies have reinforced market adoption and driven further investment in next-generation formulations.

The semaglutide industry is poised for sustained growth, supported by increasing diabetes and obesity prevalence, technological advancements in drug delivery, and ongoing R&D initiatives. While patent protections ensure near-term market exclusivity, competitive dynamics may shift as alternative formulations and combination therapies emerge. Industry participants continue to focus on expanding indications and geographic reach to capitalize on the evolving market landscape.

Semaglutide Market Report Highlights:

• Based on product, Ozempic dominated the market with a revenue share of 59.62% in 2024, driven by strong clinical efficacy, broad regulatory approvals, and increasing adoption for type 2 diabetes.
• Based on application, Type 2 Diabetes Mellitus dominated the market and accounted for a revenue share of 71.16% in 2024, driven by its rising global prevalence and increasing adoption of advanced therapies.
• Based on route of administration, parenteral route of administration dominated the market and accounted for a share of 88.46% in 2024, driven by the widespread adoption of Ozempic and Wegovy, both available as injectable formulations.
• Based on distribution channel, retail pharmacies led the market and accounted for a share of 55.09% in 2024, driven by increasing consumer demand for GLP-1 receptor agonists like Ozempic and Wegovy.
• Key market players include Novo Nordisk, Eli Lilly, Viking Therapeutics, Lexicon Pharmaceuticals, Biocon, and AstraZeneca. Competition is expected to intensify as biosimilar manufacturers enter the market after semaglutide's patent expires.
• In March 2025, Novo Nordisk's phase 3b STRIDE trial showed that Ozempic (semaglutide 1.0 mg) improved walking distance by 13% in adults with type 2 diabetes and PAD. Results were presented at ACC 2025 and published in The Lancet. Novo Nordisk has submitted a label extension application to the EMA and FDA.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. Route of Administration
  • 1.2.4. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Semaglutide Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis, by Phase
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis
  • 3.3.6. Competitive Landscape: Emerging Biosimilars in the Post-Patent Semaglutide Market

Chapter 4. Semaglutide Market: Product Business Analysis

• 4.1. Product Market Share, 2024 & 2035
• 4.2. Product Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2035 (USD Million)
• 4.4. Ozempic
  • 4.4.1. Ozempic Market, 2018 - 2035 (USD Million)
• 4.5. Wegovy
  • 4.5.1. Wegovy Market, 2018 - 2035 (USD Million)
• 4.6. Rybelsus
  • 4.6.1. Rybelsus Market, 2018 - 2035 (USD Million)
• 4.7. Others
  • 4.7.1. Other Product Market, 2018 - 2035 (USD Million)

Chapter 5. Semaglutide Market: Application Business Analysis

• 5.1. Application Market Share, 2024 & 2035
• 5.2. Application Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2035 (USD Million)
• 5.4. Type 2 Diabetes Mellitus
  • 5.4.1. Type 2 Diabetes Mellitus Market, 2018 - 2035 (USD Million)
• 5.5. Obesity
  • 5.5.1. Obesity Market, 2018 - 2035 (USD Million)
• 5.6. Others
  • 5.6.1. Others Market, 2018 - 2035 (USD Million)

Chapter 6. Semaglutide Market: Route of Administration Business Analysis

• 6.1. Route of Administration Market Share, 2024 & 2035
• 6.2. Route of Administration Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2035 (USD Million)
• 6.4. Parenteral
  • 6.4.1. Parenteral Market, 2018 - 2035 (USD Million)
• 6.5. Oral
  • 6.5.1. Oral Market, 2018 - 2035 (USD Million)

Chapter 7. Semaglutide Market: Distribution Channel Business Analysis

• 7.1. Distribution Channel Market Share, 2024 & 2035
• 7.2. Distribution Channel Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2035 (USD Million)
• 7.4. Hospital Pharmacies
  • 7.4.1. Hospital Pharmacies Market, 2018 - 2035 (USD Million)
• 7.5. Retail Pharmacies
  • 7.5.1. Retail Pharmacies Market, 2018 - 2035 (USD Million)
• 7.6. Online Pharmacies
  • 7.6.1. Online Pharmacies Market, 2018 - 2035 (USD Million)

Chapter 8. Semaglutide Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2035
• 8.2. Regional Market Dashboard
• 8.3. Market Size & Forecasts Trend Analysis, 2018 to 2035:
• 8.4. North America
  • 8.4.1. North America Semaglutide Market Estimates And Forecasts, By Country, 2018 - 2035 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Target Disease Prevalence
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Reimbursement Framework
    • 8.4.2.5. U.S. Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Target Disease Prevalence
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Reimbursement Framework
    • 8.4.3.5. U.S. Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Target Disease Prevalence
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Reimbursement Framework
    • 8.4.4.5. Mexico Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Target Disease Prevalence
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement Framework
    • 8.5.2.5. Uk Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Target Disease Prevalence
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement Framework
    • 8.5.3.5. Germany Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Target Disease Prevalence
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Reimbursement Framework
    • 8.5.4.5. France Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Target Disease Prevalence
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Reimbursement Framework
    • 8.5.5.5. Italy Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Target Disease Prevalence
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Reimbursement Framework
    • 8.5.6.5. Spain Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.5.7. Denmark
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Target Disease Prevalence
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Reimbursement Framework
    • 8.5.7.5. Denmark Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Target Disease Prevalence
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Reimbursement Framework
    • 8.5.8.5. Sweden Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Target Disease Prevalence
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Reimbursement Framework
    • 8.5.9.5. Norway Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Target Disease Prevalence
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement Framework
    • 8.6.2.5. Japan Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Target Disease Prevalence
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement Framework
    • 8.6.3.5. China Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Target Disease Prevalence
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement Framework
    • 8.6.4.5. India Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Target Disease Prevalence
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement Framework
    • 8.6.5.5. Australia Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Target Disease Prevalence
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. Reimbursement Framework
    • 8.6.6.5. South Korea Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Target Disease Prevalence
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Reimbursement Framework
    • 8.6.7.5. Thailand Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Target Disease Prevalence
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Reimbursement Framework
    • 8.7.2.5. Japan Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Target Disease Prevalence
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Reimbursement Framework
    • 8.7.3.5. China Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
• 8.8. Middle East and Africa
  • 8.8.1. Middle East and Africa Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Target Disease Prevalence
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. Reimbursement Framework
    • 8.8.2.5. South Africa Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Target Disease Prevalence
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Reimbursement Framework
    • 8.8.3.5. Saudi Arabia Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Target Disease Prevalence
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. Reimbursement Framework
    • 8.8.4.5. UAE Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Target Disease Prevalence
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Reimbursement Framework
    • 8.8.5.5. Kuwait Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position Analysis
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1. Novo Nordisk A/S
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. Eli Lilly
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. Viking Therapeutics
    • 9.5.3.1. Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. Lexicon Pharmaceuticals
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. Biocon
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. AstraZeneca
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives